Antithrombotic Therapy in Lower Extremity Artery Disease

Author(s): Mislav Vrsalovic, Victor Aboyans*

Journal Name: Current Vascular Pharmacology

Volume 18 , Issue 3 , 2020

Become EABM
Become Reviewer

Abstract:

Lower extremity artery disease (LEAD) is a marker of a more advanced atherosclerotic process often affecting multiple vascular beds beyond the lower limbs, with a consequent increased risk for all-cause and cardiovascular mortality. Antithrombotic therapy is the cornerstone of management of these patients to prevent ischaemic cardiovascular and limb events and death. In patients with symptomatic LEAD, the efficacy of aspirin has been established long ago for the prevention of cardiovascular events. In the current guidelines, clopidogrel may be preferred over aspirin following its incremental ability to prevent cardiovascular events, while ticagrelor is not superior to clopidogrel in reducing cardiovascular outcomes. Dual antiplatelet therapy (DAPT, aspirin with clopidogrel) is currently recommended for at least 1 month after endovascular interventions irrespective of the stent type. Antiplatelet monotherapy is recommended after infra-inguinal bypass surgery, and DAPT may be considered in below-the-knee bypass with a prosthetic graft. In symptomatic LEAD, the addition of anticoagulant (vitamin K antagonists) to antiplatelet therapy increased the risk of major and life-threatening bleeding without benefit regarding cardiovascular outcomes. In a recent trial, low dose of direct oral anticoagulant rivaroxaban plus aspirin showed promising results, not only to reduce death and major cardiovascular events, but also major limb events including amputation. Yet, this option should be considered especially in very high risk patients, after considering also the bleeding risk. Despite all the evidence accumulated since >40 years, many patients with LEAD remain undertreated and deserve close attention and implementation of guidelines advocating the use of antithrombotic therapies, tailored according to their level of risk.

Keywords: Lower extremity artery disease, peripheral arterial disease, antiplatelet therapy, antithrombotic therapy, direct oral anticoagulants, atherosclerosis.

[1]
Eurostat. Causes of death - Cardiovascular diseases statistics, data extracted in September 2018. Available from:. http://ec.europa.eu/eurostat/
[2]
Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015; 116(9): 1509-26.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.303849] [PMID: 25908725]
[3]
Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the european society for vascular surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: the European stroke organization (ESO). The task force for the diagnosis and treatment of peripheral arterial diseases of the European society of cardiology (ESC) and of the European society for vascular surgery (ESVS). Eur Heart J 2018; 39(9): 763-816.
[http://dx.doi.org/10.1093/eurheartj/ehx095] [PMID: 28886620]
[4]
Vrsalović M, Vučur K, Car B, Krčmar T, Vrsalović Presečki A. C-reactive protein, renal function, and cardiovascular outcome in patients with symptomatic peripheral artery disease and preserved left ventricular systolic function. Croat Med J 2015; 56(4): 351-6.
[http://dx.doi.org/10.3325/cmj.2015.56.351] [PMID: 26321028]
[5]
Alberts MJ, Bhatt DL, Mas JL, et al. Reduction of atherothrombosis for continued health registry investigators. three-year follow-up and event rates in the international reduction of atherothrombosis for continued health (REACH) registry. Eur Heart J 2009; 30: 2318-26.
[http://dx.doi.org/10.1093/eurheartj/ehp355] [PMID: 19720633]
[6]
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315-81.
[http://dx.doi.org/10.1093/eurheartj/ehw106] [PMID: 27222591]
[7]
Vrsalovic M, Vucur K, Vrsalovic Presecki A, Fabijanic D, Milosevic M. Impact of diabetes on mortality in peripheral artery disease: a meta-analysis. Clin Cardiol 2017; 40(5): 287-91.
[http://dx.doi.org/10.1002/clc.22657] [PMID: 28026025]
[8]
Kumbhani DJ, Steg PG, Cannon CP, et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 2014; 35(41): 2864-72.
[http://dx.doi.org/10.1093/eurheartj/ehu080] [PMID: 24585266]
[9]
Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc 2014; 3(2)e000697
[http://dx.doi.org/10.1161/JAHA.113.000697] [PMID: 24721799]
[10]
Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
[http://dx.doi.org/10.1136/bmj.a1840] [PMID: 18927173]
[11]
Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303(9): 841-8.
[http://dx.doi.org/10.1001/jama.2010.221] [PMID: 20197530]
[12]
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71-86.
[http://dx.doi.org/10.1136/bmj.324.7329.71] [PMID: 11786451]
[13]
Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 2007; 261(3): 276-84.
[http://dx.doi.org/10.1111/j.1365-2796.2006.01763.x] [PMID: 17305650]
[14]
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348(9038): 1329-39.
[http://dx.doi.org/10.1016/S0140-6736(96)09457-3] [PMID: 8918275]
[15]
Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49(19): 1982-8.
[http://dx.doi.org/10.1016/j.jacc.2007.03.025] [PMID: 17498584]
[16]
Hiatt WR, Fowkes FG, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017; 376(1): 32-40.
[http://dx.doi.org/10.1056/NEJMoa1611688] [PMID: 27959717]
[17]
Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2degreesP-TIMI 50. Circulation 2013; 127(14): 1522-29.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.000679] [PMID: 23501976]
[18]
Tepe G, Bantleon R, Brechtel K, et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy--the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol 2012; 22(9): 1998-2006.
[http://dx.doi.org/10.1007/s00330-012-2441-2] [PMID: 22569995]
[19]
Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the zilver PTX randomized trial. Circulation 2016; 133(15): 1472-83.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.016900] [PMID: 26969758]
[20]
Laird JR, Schneider PA, Tepe G, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol 2015; 66(21): 2329-38.
[http://dx.doi.org/10.1016/j.jacc.2015.09.063] [PMID: 26476467]
[21]
Bedenis R, Lethaby A, Maxwell H, Acosta S, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2015; 2 CD000535
[http://dx.doi.org/10.1002/14651858.CD000535.pub3] [PMID: 25695213]
[22]
Belch JJ, Dormandy J, Biasi GM, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52(4): 825-33.
[http://dx.doi.org/10.1016/j.jvs.2010.04.027] [PMID: 20678878]
[23]
Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev 2014; 5 CD001999
[http://dx.doi.org/10.1002/14651858.CD001999.pub2] [PMID: 24801382]
[24]
Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000; 355(9201): 346-51.
[http://dx.doi.org/10.1016/S0140-6736(99)07199-8] [PMID: 10665553]
[25]
Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357(3): 217-27.
[http://dx.doi.org/10.1056/NEJMoa065959] [PMID: 17634457]
[26]
Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 377: 1319-30.
[PMID: 29132879]
[27]
Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391(10117): 219-29.
[http://dx.doi.org/10.1016/S0140-6736(17)32409-1] [PMID: 29132880]
[28]
Anand SS, Caron F, Eikelboom JW, et al. Major adverse limb events and mortality in patients with peripheral artery disease: The COMPASS trial. J Am Coll Cardiol 2018; 71(20): 2306-15.
[http://dx.doi.org/10.1016/j.jacc.2018.03.008] [PMID: 29540326]
[29]
Moll F, Baumgartner I, Jaff M, et al. Edoxaban plus aspirin vs. dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD trial. J Endovasc Ther 2018; 25(2): 158-68.
[http://dx.doi.org/10.1177/1526602818760488] [PMID: 29552984]
[30]
Capell WH, Bonaca MP, Nehler MR, et al. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J 2018; 199: 83-91.
[http://dx.doi.org/10.1016/j.ahj.2018.01.011] [PMID: 29754671]
[31]
Habib A, Petrucci G, Rocca B. Pathophysiology of thrombosis in peripheral artery disease. Curr Vasc Pharmacol 2020; 18: 204-14.
[PMID: 30727897]
[32]
Jagroop IA, Matsagas MI, Geroulakos G, Mikhailidis DP. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets 2004; 15(2): 117-25.
[http://dx.doi.org/10.1080/09537105310001645960] [PMID: 15154604]
[33]
Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol 2016; 67(23): 2719-28.
[http://dx.doi.org/10.1016/j.jacc.2016.03.524] [PMID: 27046162]
[34]
Franzone A, Piccolo R, Gargiulo G, et al. Prolonged vs. short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: a subgroup analysis of the PRODIGY randomized clinical trial. JAMA Cardiol 2016; 1(7): 795-803.
[http://dx.doi.org/10.1001/jamacardio.2016.2811] [PMID: 27572001]
[35]
Secemsky EA, Yeh RW, Kereiakes DJ, et al. Extended duration dual antiplatelet therapy after coronary stenting among patients with peripheral arterial disease: a subanalysis of the dual antiplatelet therapy study. JACC Cardiovasc Interv 2017; 10(9): 942-54.
[http://dx.doi.org/10.1016/j.jcin.2017.02.013] [PMID: 28473118]
[36]
Vrsalovic M, Vucur K, Jelakovic B. atrial fibrillation predicts cardiovascular outcome in hypertensive patients with symptomatic peripheral artery disease and preserved ejection fraction. J Clin Hypertens (Greenwich) 2016; 18(9): 953-4.
[http://dx.doi.org/10.1111/jch.12815] [PMID: 26990001]
[37]
Vrsalović M, Presečki AV. Atrial fibrillation and risk of cardiovascular events and mortality in patients with symptomatic peripheral artery disease: A meta-analysis of prospective studies. Clin Cardiol 2017; 40(12): 1231-5.
[http://dx.doi.org/10.1002/clc.22813] [PMID: 29243858]
[38]
Alatri A, Mazzolai L. The bleeding risk in antithrombotic therapies: a narrative review. Curr Vasc Pharmacol 2020; 18: 236-47.
[http://dx.doi.org/10.2174/1570161117666190212112743] [PMID: 30747072]
[39]
Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014; 35(35): 2383-431.
[http://dx.doi.org/10.1093/eurheartj/ehu282] [PMID: 25086026]
[40]
De Carlo M, Angelillis M, Liga R. Antithrombotic therapy for peripheral revascularization. Curr Vasc Pharmacol 2020; 18: 223-35.
[http://dx.doi.org/10.2174/1570161117666190206234606]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 3
Year: 2020
Page: [215 - 222]
Pages: 8
DOI: 10.2174/1570161117666190206230516
Price: $65

Article Metrics

PDF: 31
HTML: 4
EPUB: 1
PRC: 1